Post-Treatment Circulating Free HPV DNAAs a Marker of Treatment Outcome inPatients with HPV-Related PropharyngealCancer After Radio(chemo)therapy
Post-Treatment Circulating Free HPV DNAAs a Marker of Treatment Outcome inPatients with HPV-Related PropharyngealCancer After Radio(chemo)therapy
复制标题
治疗后循环游离 HPV DNA 作为 HPV 相关原咽癌放（化疗）治疗后治疗结果的标志
DOI：
10.21767/2573-5365.100035
复制
发表时间：
2017
影响因子：
5.5
通讯作者：
P. WidÅak
中科院分区：
文献类型：
--
作者：
T. Rutkowski;A. Mazurek;M. Ånietura;A. Wygoda;W. PigÅowski;Z. KoÅosza;K. SkÅadowski;P. WidÅak
Circulating cell-free HPV16 DNA (cfHPV DNA) assessed after treatment completion was tested as a prognostic marker of treatment failure in patients with HPVrelated oropharyngeal cancer (OPC) treated with radiotherapy alone (RT) or radiotherapy combined with chemotherapy (CHRT). Fifty-five patients with OPC in whom cfHPV DNA was found prior to RT/CHRT were included into the study. cfHPV DNA was subsequently assessed after treatment completion. cfHPV DNA remission (cfHPVrem) was defined as the absence of cfHPV DNA after treatment completion. The association between cfHPVrem and the risk of local, nodal or distant failure was calculated. Survival curves were calculated according to the Kaplan-Meier technique and compared according to cfHPVrem after treatment completion with the log-rank test. Thirteen (24%) patients presented no cfHPVrem after treatment completion. For these patients, the risk of nodal failure was significantly higher (HR=9.38, 95% CI: 1.63-53.97, p=0.009) than for patients with cfHPVrem. The probability of dissemination was comparable in patients with cfHPVrem and with no cfHPVrem (p=0.95). For patients with HPV related OPC, who has no cfHPVrem after RT/CHRT completion stricter follow up is proposed due to higher risk of nodal failure.
登录
查看更多内容
影响因子：
28.4
作者：
Rettig EM;Wentz A;Posner MR;Gross ND;Haddad RI;Gillison ML;Fakhry C;Quon H;Sikora AG;Stott WJ;Lorch JH;Gourin CG;Guo Y;Xiao W;Miles BA;Richmon JD;Andersen PE;Misiukiewicz KJ;Chung CH;Gerber JE;Rajan SD;D'Souza G
通讯作者：
D'Souza G
DOI：
10.1056/nejmoa0912217
发表时间：
2010-07-01
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ang KK;Harris J;Wheeler R;Weber R;Rosenthal DI;Nguyen-Tân PF;Westra WH;Chung CH;Jordan RC;Lu C;Kim H;Axelrod R;Silverman CC;Redmond KP;Gillison ML
通讯作者：
Gillison ML
DOI：
10.1016/j.ejca.2015.09.005
发表时间：
2015-12
期刊：
European journal of cancer (Oxford, England : 1990)
影响因子：
--
作者：
Goodman MT;Saraiya M;Thompson TD;Steinau M;Hernandez BY;Lynch CF;Lyu CW;Wilkinson EJ;Tucker T;Copeland G;Peters ES;Altekruse S;Unger ER
通讯作者：
Unger ER
影响因子：
6.2
作者：
Guo, Theresa;Qualliotine, Jesse R.;Ha, Patrick K.;Califano, Joseph A.;Kim, Young;Saunders, John R.;Blanco, Ray G.;D'Souza, Gypsyamber;Zhang, Zhe;Chung, Christine H.;Kiess, Ana;Gourin, Christine G.;Koch, Wayne;Richmon, Jeremy D.;Agrawal, Nishant;Eisele, David W.;Fakhry, Carole
通讯作者：
Fakhry, Carole